title: Etiological factors in primary hepatic B-cell lymphoma.
abstract: Sixty-four cases of malignant lymphoma involving the liver were examined. Of these, 20 cases were histologically confirmed to be primary hepatic B-cell lymphoma. Twelve of these 20 cases were diffuse large B-cell lymphoma (DLBCL) and eight cases were mucosa-associated lymphoid tissue (MALT) lymphoma. Of the 12 cases of DLBCL, six were immunohistologically positive for CD10 and/or Bcl6 (indicating a germinal center phenotype), six were positive for Bcl2, and five were positive for CD25. Eight of the 12 DLBCL cases (66.7%) and two of the eight MALT lymphoma cases (25%) had serum anti-hepatitis C virus (HCV) antibodies and HCV RNA. The incidence of HCV infection was significantly higher in the hepatic DLBCL cases than in systemic intravascular large B-cell cases with liver involvement (one of 11 cases, 9.1%) and T/NK-cell lymphoma cases (one of 19 cases, 5.3%) (p < 0.01 for both). Two hepatic DLBCL cases (16.7%) had rheumatoid arthritis treated with methotrexate, and four MALT lymphoma cases (50%) had Sjögren's syndrome, primary biliary cirrhosis, or autoimmune hepatitis; one case in each of these two groups was complicated by chronic HCV-seropositive hepatitis. Although primary hepatic lymphoma is rare, persistent inflammatory processes associated with HCV infection or autoimmune disease may play independent roles in the lymphomagenesis of hepatic B cells.
authors.affiliation: Departments of Pathology and Internal Medicine, Faculty of Medicine, Fukuoka University, Nanakuma 7-45-1, Johnan-ku, Fukuoka, Japan.
authors.forename: Kanta
authors.initials: K
authors.lastname: Kikuma
authors.forename: Jiro
authors.initials: J
authors.lastname: Watanabe
authors.forename: Yumi
authors.initials: Y
authors.lastname: Oshiro
authors.forename: Tatsuo
authors.initials: T
authors.lastname: Shimogama
authors.forename: Yumi
authors.initials: Y
authors.lastname: Honda
authors.forename: Seiichi
authors.initials: S
authors.lastname: Okamura
authors.forename: Koichi
authors.initials: K
authors.lastname: Higaki
authors.forename: Naokuni
authors.initials: N
authors.lastname: Uike
authors.forename: Tetsuro
authors.initials: T
authors.lastname: Soda
authors.forename: Seiya
authors.initials: S
authors.lastname: Momosaki
authors.forename: Tadaaki
authors.initials: T
authors.lastname: Yokota
authors.forename: Satoshi
authors.initials: S
authors.lastname: Toyoshima
authors.forename: Morishige
authors.initials: M
authors.lastname: Takeshita
mesh_terms: D000368:Aged; D001402:B-Lymphocytes / Q000473:pathology; D005260:Female; D016174:Hepacivirus / Q000276:immunology; D006513:Hepatitis B e Antigens / Q000032:analysis; D006526:Hepatitis C / Q000150:complications*; D018937:Hepatitis C Antibodies / Q000032:analysis; D006801:Humans; D008113:Liver Neoplasms / Q000473:pathology*; D016393:Lymphoma, B-Cell / Q000150:complications / Q000473:pathology*; D016403:Lymphoma, Large B-Cell, Diffuse / Q000150:complications / Q000473:pathology*; D008297:Male; D008875:Middle Aged; D016019:Survival Analysis
chemical_list: D006513:Hepatitis B e Antigens; D018937:Hepatitis C Antibodies